Global Doxercalciferol Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Doxercalciferol Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease. It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion.
Doxercalciferol report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Doxercalciferol market is projected to reach US$ 521.7 million in 2029, increasing from US$ 354 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2029. Demand from SHPT in patients with CKD on dialysis and SHPT in patients with stage 3 or stage 4 CKD are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Doxercalciferol industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Doxercalciferol key manufacturers include Sanofi, Prasco Laboratories, Hikma Pharmaceuticals, Amneal Pharms, Pfizer, Akorn and West-Ward Pharmaceuticals, etc. Sanofi, Prasco Laboratories, Hikma Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Doxercalciferol can be divided into Injection and Capsule, etc. Injection is the mainstream product in the market, accounting for % sales share globally in 2022.
Doxercalciferol is widely used in various fields, such as SHPT in patients with CKD on dialysis and SHPT in patients with stage 3 or stage 4 CKD, etc. SHPT in patients with CKD on dialysis provides greatest supports to the Doxercalciferol industry development. In 2022, global % sales of Doxercalciferol went into SHPT in patients with CKD on dialysis filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Doxercalciferol market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi
Prasco Laboratories
Hikma Pharmaceuticals
Amneal Pharms
Pfizer
Akorn
West-Ward Pharmaceuticals
Segment by Type
Injection
Capsule
SHPT in patients with CKD on dialysis
SHPT in patients with stage 3 or stage 4 CKD
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Doxercalciferol market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Doxercalciferol, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Doxercalciferol industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Doxercalciferol in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Doxercalciferol introduction, etc. Doxercalciferol Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Doxercalciferol market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Doxercalciferol report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Doxercalciferol market is projected to reach US$ 521.7 million in 2029, increasing from US$ 354 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2029. Demand from SHPT in patients with CKD on dialysis and SHPT in patients with stage 3 or stage 4 CKD are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Doxercalciferol industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Doxercalciferol key manufacturers include Sanofi, Prasco Laboratories, Hikma Pharmaceuticals, Amneal Pharms, Pfizer, Akorn and West-Ward Pharmaceuticals, etc. Sanofi, Prasco Laboratories, Hikma Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Doxercalciferol can be divided into Injection and Capsule, etc. Injection is the mainstream product in the market, accounting for % sales share globally in 2022.
Doxercalciferol is widely used in various fields, such as SHPT in patients with CKD on dialysis and SHPT in patients with stage 3 or stage 4 CKD, etc. SHPT in patients with CKD on dialysis provides greatest supports to the Doxercalciferol industry development. In 2022, global % sales of Doxercalciferol went into SHPT in patients with CKD on dialysis filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Doxercalciferol market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi
Prasco Laboratories
Hikma Pharmaceuticals
Amneal Pharms
Pfizer
Akorn
West-Ward Pharmaceuticals
Segment by Type
Injection
Capsule
Segment by Application
SHPT in patients with CKD on dialysis
SHPT in patients with stage 3 or stage 4 CKD
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Doxercalciferol market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Doxercalciferol, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Doxercalciferol industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Doxercalciferol in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Doxercalciferol introduction, etc. Doxercalciferol Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Doxercalciferol market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices